Literature DB >> 33586996

Short Communication: Update in Natural Antiretroviral Resistance-Associated Mutations Among HIV Type 2 Variants and Discrepancies Across HIV Type 2 Resistance Interpretation Tools.

Paloma Troyano-Hernáez1, Roberto Reinosa1, María Concepción Burgos1, África Holguín1.   

Abstract

HIV variants carry natural polymorphisms related to drug resistance (R-markers) fixed during viral evolution in the absence of antiretroviral therapy (ART) that may impact on drug susceptibility and resistance pathways. We aimed to identify the HIV type 2 (HIV-2) variant-specific R-markers at Pol in all available sequences from ART-naive subjects deposited in Los Alamos database according to reported HIV-2 drug resistance-associated mutations (DRMs) and report the performance of two online HIV-2 resistance interpretation tools (HIV2EU Tool and Stanford HIVdb Program for HIV-2) to detect them. From a total of 587 sequences, we found 23 R-markers in low frequency, in groups A, B, and G. Four were present in >10% of the sequences with no direct impact on antiretroviral susceptibility. HIV2EU Tool detected one, whereas Stanford program all four. Stanford new tool, although still under development, seems effective in detecting HIV-2 DRMs and may prove a useful tool for HIV-2 resistance interpretation when fully developed.

Entities:  

Keywords:  HIV-2; drug resistance mutation; variants

Mesh:

Substances:

Year:  2021        PMID: 33586996     DOI: 10.1089/AID.2020.0180

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; África Holguín
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; África Holguín
Journal:  Front Microbiol       Date:  2022-04-12       Impact factor: 5.640

3.  Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; Africa Holguín
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.